{"filing":{"accession_number":"0001628280-26-043431","cik":"0001818331","ticker":"WGSWW","company_name":"GeneDx Holdings Corp.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"wgs-20260615.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818331/000162828026043431/wgs-20260615.htm"},"events":[{"id":11227,"run_id":9846,"accession_number":"0001628280-26-043431","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"GeneDx Holdings Corp. appointed Mark Gardner as President, effective June 15, 2026, with a $530,000 base salary, 65% target bonus, and $2,000,000 in restricted stock units vesting over four years.","company_name":"GeneDx Holdings Corp.","ticker":"WGSWW","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7765,"accession_number":"0001628280-26-043431","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Mark Gardner as President of GeneDx Holdings Corp., effective June 15, 2026, with detailed compensation arrangements including a $530,000 base salary, 65% target bonus, and $2,000,000 in restricted stock units vesting over four years. This is a material executive appointment that would affect a reasonable investor's assessment of the company's leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T12:41:08.214095+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7766,"accession_number":"0001628280-26-043431","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Mr. Gardner's appointment as President via press release dated June 16, 2026. This is a material executive appointment to a senior officer role. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is clearly an executive appointment that would affect a reasonable investor's assessment of company leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T12:41:08.214095+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7765,"accession_number":"0001628280-26-043431","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Mark Gardner as President of GeneDx Holdings Corp., effective June 15, 2026, with detailed compensation arrangements including a $530,000 base salary, 65% target bonus, and $2,000,000 in restricted stock units vesting over four years. This is a material executive appointment that would affect a reasonable investor's assessment of the company's leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T12:41:08.214095+00:00","company_name":"GeneDx Holdings Corp.","ticker":"WGSWW","filing_date":"2026-06-16"},{"id":7766,"accession_number":"0001628280-26-043431","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Mr. Gardner's appointment as President via press release dated June 16, 2026. This is a material executive appointment to a senior officer role. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is clearly an executive appointment that would affect a reasonable investor's assessment of company leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T12:41:08.214095+00:00","company_name":"GeneDx Holdings Corp.","ticker":"WGSWW","filing_date":"2026-06-16"}]}